Marie Luise Hütter-Krönke

Marie Luise Hütter-Krönke

Auto-generated profile, based on publicly available information

Marie Luise Hütter-Krönke

Department of Hematology, Oncology and Cancer Immunology, Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Blood
Verified
Journal Article
Open access
DKDavid John Kuter
David John Kuter
WGWaleed Ghanima
Waleed Ghanima
NCNichola Cooper
Nichola Cooper
HLHoward A. Liebman
Howard A. Liebman
LZLei Zhang
Lei Zhang
ADAhmed Daak
Ahmed Daak
Rilzabrutinib is a covalent, reversible Bruton tyrosine kinase inhibitor targeting multiple immune thrombocytopenia (ITP)-related mechanisms. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg twice daily (n = 133) vs placebo (n = 69) for 24 weeks. At baseline overall, median age was 47 years, 63% female, 7.7 year median ITP duration, and 28% prior splenectomy. Overall (N = 202), 85 (64%) rilzabrutinib and 22 (32%) placebo patients achieved platelet response (≥50 × 109/L or 30 × 109/L to <50 × 109/L and doubled from baseline) during the first 12 weeks and were eligible to continue. The primary end point, durable platelet response (platelet count ≥50 × 109/L for ≥two-thirds of ≥8 of the last 12 of 24 weeks without rescue therapy), was observed in 31 (23%) rilzabrutinib vs 0 placebo patients (P < .0001). All secondary efficacy end points were significantly superior for rilzabrutinib (P < .05). Median time to first platelet response was 15 days in rilzabrutinib responders. Rilzabrutinib significantly reduced rescue therapy use by 52% (P = .0007) and improved week 25 bleeding scores (P = .0006). Improved physical fatigue was sustained from week 13 (P = .01) through 25 (P = .0003). Treatment-related adverse events were mainly grade 1/2. One rilzabrutinib patient with multiple risk factors had serious treatment-related grade 3 peripheral embolism (lower left leg), and another died from unrelated pneumonia. Rilzabrutinib in patients who failed multiple previous ITP therapies showed rapid and durable platelet response, reduced rescue medication and bleeding, improved physical fatigue, and favorable safety. Trial registration: www.clinicaltrials.gov (#NCT04562766) and www.clinicaltrialsregister.eu (#2020-002063-60).

22 March 2024 in Journal of Medical Virology
Verified
Journal Article
Open access
ETEva Tranter
Eva Tranter
MFMarco Frentsch
Marco Frentsch
MHMarie Luise Hütter‐Krönke
Marie Luise Hütter‐Krönke
GVGiang Lam Vuong
Giang Lam Vuong
DBDavid Busch
David Busch
INIl-Kang Na
Il-Kang Na
Despite extensive research on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination responses in healthy individuals, there is comparatively little known beyond antibody titers and T‐cell responses in the vulnerable cohort of patients after allogeneic hematopoietic stem cell transplantation (ASCT). In this study, we assessed the serological response and performed longitudinal multimodal analyses including T‐cell functionality and single‐cell RNA sequencing combined with T cell receptor (TCR)/B cell receptor (BCR) profiling in the context of BNT162b2 vaccination in ASCT patients. In addition, these data were compared to publicly available data sets of healthy vaccinees. Protective antibody titers were achieved in 40% of patients. We identified a distorted B‐ and T‐cell distribution, a reduced TCR diversity, and increased levels of exhaustion marker expression as possible causes for the poorer vaccine response rates in ASCT patients. Immunoglobulin heavy chain gene rearrangement after vaccination proved to be highly variable in ASCT patients. Changes in TCRα and TCRβ gene rearrangement after vaccination differed from patterns observed in healthy vaccinees. Crucially, ASCT patients elicited comparable proportions of SARS‐CoV‐2 vaccine‐induced (VI) CD8+ T‐cells, characterized by a distinct gene expression pattern that is associated with SARS‐CoV‐2 specificity in healthy individuals. Our study underlines the impaired immune system and thus the lower vaccine response rates in ASCT patients. However, since protective vaccine responses and VI CD8+ T‐cells can be induced in part of ASCT patients, our data advocate early posttransplant vaccination due to the high risk of infection in this vulnerable group.

27 August 2026 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
FAFredrik N. Albach
Fredrik N. Albach
MRMarie C. Rehm
Marie C. Rehm
MHMarie Luise Hütter-Krönke
Marie Luise Hütter-Krönke
TLThanh Hang Le
Thanh Hang Le
JGJulia M. Giezen
Julia M. Giezen
GKGerhard Krönke
Gerhard Krönke

20 May 2026 in Blood Immunology & Cellular Therapy
Verified
Journal Article
Open access
MKMichael Korenkov
Michael Korenkov
MZMaximilian Rudolf Zuleeg
Maximilian Rudolf Zuleeg
JLJulian Liebaert
Julian Liebaert
VFVincent Fregona
Vincent Fregona
SSSebastian Serve
Sebastian Serve
MHMarie Luise Hütter-Krönke
Marie Luise Hütter-Krönke